5.59 0.00 (0.00%)
After hours: 4:53PM EDT
|Bid||5.31 x 900|
|Ask||5.65 x 2900|
|Day's Range||5.40 - 5.71|
|52 Week Range||5.34 - 17.40|
|Beta (3Y Monthly)||1.32|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
How far off is Five Prime Therapeutics, Inc. (NASDAQ:FPRX) from its intrinsic value? Using the most recent financial...
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]
Five Prime Therapeutics Inc NASDAQ/NGS:FPRXView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low and declining * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for FPRX with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on June 14. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding FPRX is favorable, with net inflows of $2.40 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of 4.67% and -6.36%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the South San Francisco, California-based company said it had a loss of $1.02. The results topped Wall Street expectations. The average estimate of seven analysts surveyed by Zacks ...
Five Prime Therapeutics (FPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
This Peninsula drug developer has four preclinical drugs aimed at triggering a process that it believes will kill cancer cells with genetic mutations.
In December 2018, Five Prime Therapeutics, Inc. (NASDAQ:FPRX) released its latest earnings announcement, which showed company earnings became less negative compared to the previous year's level - gre...
How Genentech — with the help of a $1.7 billion merger — is breaking new ground in cancer … and more in our Health Care Digest.
Five Prime (FPRX) recently held a quarterly conference call and, importantly, all of the company's timelines remain on track; it has developed a broad pipeline with five drug candidates now in human clinical development, observes John McCamant, biotech expert and editor of The Medical Technology Stock Letter.